tm logo

Monitor this mark

View On USPTO

IMBRIA
Live/Pending
THIRD EXTENSION - GRANTED

granted

on 04 Sep 2024

Last Applicant/ Owned by

Imbria Pharmaceuticals, Inc.

265 Franklin Street, Suite 1702

Boston

MA

02110

Serial Number

88193539 filed on 14th Nov 2018

Registration Number

N/A

Correspondent Address

John Paul Oleksiuk

John Paul Oleksiuk COOLEY LLP

WASHINGTON, DC 20004-2400

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

IMBRIA

Pharmaceuticals for treatment of mitochondrial disorders, genetic diseases, neurological diseases, renal diseases, and blood diseases

Classification Information

Class [005]
Pharmaceutical Products

Pharmaceuticals for treatment of mitochondrial disorders, genetic diseases, neurological diseases, renal diseases, and blood diseases

First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details

Serial Number

No 88193539

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 334639-20003

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History

Show more

Status DateAction Taken
04th Sep 2024SOU EXTENSION 3 FILED
04th Sep 2024SOU EXTENSION 3 GRANTED
04th Sep 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04th Sep 2024SOU TEAS EXTENSION RECEIVED
23rd Apr 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22nd Apr 2024SOU EXTENSION 2 GRANTED
22nd Apr 2024SOU EXTENSION 2 FILED
22nd Apr 2024SOU TEAS EXTENSION RECEIVED
01st Dec 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01st Dec 2023CORRECTED NOA E-MAILED